HLE Glascoat Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Glass-lined business collapsed, dragging margins to ~3%: India glass-lined revenue fell 30% YoY in Q4 as chemical-sector customers deferred deliveries and orders, compressing EBIT margins to roughly 3% on fixed-cost absorption.
• Recovery bet rests on H2, not H1: Management expects only a slight sequential margin improvement in H1 FY25, with the real rebound in volumes and margins (16–17% EBITDA) pushed to H2, when H1 orders convert to dispatches.
• Kinam and F&D are the offsetting growth engines: The Kinam acquisition lifted heat transfer, while filtration & drying grew ~10% to ₹370 crores; Kinam alone is guided to ₹180–200 crores revenue at 25–26% margins in FY25.
• Working capital stretched modestly by deferrals: About ₹20 crores of finished goods await customer acceptance, adding to the balance-sheet skew from the Kinam consolidation.
• What to watch next quarter: Whether the claimed improvement in inquiry-to-order conversion sustains into Q2, any further customer deferrals, and the pace of debt reduction against the sub-1.5x debt/EBITDA target.

The Glass-Lined Collapse & Recovery Thesis

• Volume-driven margin compression: India glass-lined EBIT margins fell to almost 3% in Q4 because fixed costs stayed flat while revenue dropped ~30% YoY; a 5–7% price erosion across the cycle added to the squeeze.
• Deferrals, not cancellations: Customers delayed both order finalisation and dispatch acceptance, stretching working capital by ~₹20 crores; management frames this as a timing issue, not lost demand.
• Conversion now improving: Unlike the post-Q2 period last year when inquiries were strong but conversion stalled, management now sees "substantial conversions" happening, which underpins the H2 recovery call.
• No capacity cuts: Management explicitly rejects scaling down operational capability because it views the volume dip as cyclical, not permanent; the focus is on improving spending quality rather than plain cost reduction.

Aalap Patel: "The biggest difference between what we had in Q2 versus or rather after the end of Q2 last year and now is that we had a strong order inquiry at the point, but then conversion was a challenge. But as it stands today, we are also seeing substantial conversions happen. So, that's what gives us that confidence."

Segment-Level Performance

End-Market Demand

• Pharma is the bright spot: Stable for two quarters and investing; pharma is now the predominant end-market internationally, including one of the largest projects in the international pipeline.
• Agro and dyestuff still waiting: Agrochemical inquiries are returning after being "almost absent" last quarter, but orders have not yet materialised; dyestuff demand is back to ~70% levels but pricing has not improved.
• Specialty chemicals in between: Positioned somewhere between the strength of pharma and the weakness of agro.
• Geographic picture is flat with a shift: US and Western Europe are stable with no major movement either way; price-sensitive European markets are filling the gap left by softer Western European demand.

Kinam, Thaletec & the Acquisition Payback

• Kinam consolidation deepening: The board approved an additional 34.44% profit-share acquisition, subject to NCLT approval via amalgamation of KEPL into HLE; this increases controlling interest beyond the initial 35.56% acquired in September 2023.
• Kinam margin premium: Guided to sustain 25–26% margins on ₹180–200 crores revenue in FY25, well above the blended company average.
• Thaletec already paid back: Acquired at a 3.5x multiple, management states Thaletec has already returned its acquisition cost; Thaletec products are now being both booked and delivered in India.
• Thaletec margin headwind: German industry-wide wage agreements pushed manpower costs above 30% of sales, capping margins at just over 10% with a FY25 trajectory of ~12%.

Management: "Thaletec, I think, if you actually look at it from a payback perspective, I think Thaletec as an acquisition has already paid back for itself. So to that extent, because we acquired it at a multiple of 3.5."

Margins: The H1/H2 Bridge

• H1 only slightly better than H2 FY24: Margins in the first half are expected to be only marginally above the depressed H2 FY24 levels, because orders booked in H1 take a full production cycle to convert to dispatches and revenue.
• H2 is where normalisation lives: Management guides H2 EBITDA margins returning to 16–17%, driven by volume recovery on the same fixed-cost base; blended glass-lined margins are guided to 13–15% for the full year.
• F&D margin anchor: Filtration & drying margins are expected to hold at 17–18% through the full year, providing a steadier contribution while glass-lined recovers.
• Cost approach is qualitative, not quantitative: Management declined to enumerate specific cost-saving metrics, framing the effort as "improvement in the quality of spending" rather than headcount or capacity reduction.

Management: "Cost savings are normally looked at very aggressively when you see a permanent dip in volumes. We do not believe this is a permanent dip in volumes and hence we are not looking at scaling down operational capabilities. So what we are really looking at is an improvement in the quality of spending."

Balance Sheet & Capital Allocation

• Debt reduction is planned, not quantified: Management targets keeping debt/EBITDA below 1.5x and intends to reduce absolute debt during FY25, but gave no specific quantum.
• No capacity capex: Zero capital outlay planned for new production capacity; maintenance capex is ~₹10 crores across India's four plants and ~€0.1 crore for Thaletec.
• CWIP tied to R&D: The ₹20 crores of capital work-in-progress relates to civil construction and an R&D centre in Anand.
• Goodwill tested, not amortised: Per accounting standards, goodwill and intangibles from acquisitions will be tested for impairment annually rather than amortised.

Guidance & Commitments

Key Metrics